Company profile
Aukera Therapeutics GmbH
Aukera Therapeutics is a spin-off from the Biozentrum of the University of Basel. Our discovery engine enables the development of new classes of pharmaceutical drugs to selectively target different branches of the mTOR pathway.
Source: startup.ch
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". 
